Elanco Animal Health says its Canine Parvovirus Monoclonal Antibody (CPMA) has received full approval from the U.S. Department of Agriculture (USDA) and will now be marketed under a new name, Trutect (Dec. 15, 2025), joining the company’s “Tru” portfolio, according to an Elanco statement.

The move upgrades CPMA from its conditional USDA license granted in May 2023 to full approval, reinforcing what Elanco positions as a major step forward in a disease area historically limited to supportive care rather than a targeted therapeutic option. Canine parvovirus remains a high-impact, high-cost emergency presentation for clinics and shelters, and Elanco cites an estimated more than 330,000 puppies affected annually in the U.S., with mortality reaching up to 91% without supportive care.

Elanco’s U.S. Pet Health and Global Digital Transformation Executive Vice President Bobby Modi framed the approval as a milestone tied to the company’s veterinary and pet owner commitments, stating that the mission “remains the same, to save puppies from parvovirus.”

Real-world clinic outcomes and operational impact

Elanco points to early field performance data from CPMA’s first year on the market, highlighting both medical and practice-level outcomes. In “real-world usage,” the company says 93% of treated puppies survived, and parvo patients treated with CPMA spent an average of 1.87 fewer days hospitalized. Elanco also reports practice feedback metrics, including that 92% of veterinarians using CPMA said it reduced overall clinic stress, alongside 90% clinic satisfaction and 83% recommending it to peers.

Elanco veterinarian Dr. Jill Pattee said these results indicate improved survival and operational efficiency for clinics incorporating the product into protocols, describing the treatment as already “re-writing the protocol” for parvovirus care.

Prevention use expands addressable demand

A key commercial and clinical development came earlier in 2025: Elanco notes that in June 2025 the USDA approved CPMA/Trutect for passive immunity, enabling veterinarians to use it as a prophylactic option for puppies exposed to parvovirus. Elanco also references a clinical study in which CPMA at a prophylactic dose was reported as 100% effective at providing passive immunity to healthy dogs 8 weeks of age or older, with no treated dogs developing parvo infection.

Access initiatives and manufacturing investment

On the access side, Elanco says it donated more than $3 million worth of product to 2,300 clinics and shelters in high-parvo areas and is offering a $200 rebate for pet owners whose puppies have been infected or exposed.

The company also links Trutect to longer-term platform investment, citing expansion work and continued investment at its Elwood, Kansas manufacturing facility to grow Elanco’s monoclonal antibody (mAb) platform.